GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (OTCPK:KNTPF) » Definitions » Growth Rank

KNTPF (Kintor Pharmaceutical) Growth Rank : 0 (As of Apr. 01, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Growth Rank?

Kintor Pharmaceutical has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Kintor Pharmaceutical Growth Rank Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (OTCPK:KNTPF) » Definitions » Growth Rank
Comparable Companies
HKSE:02185 HKSE:02898 HKSE:06628 HKSE:02126 HKSE:00690 HKSE:02257 HKSE:02511 HKSE:02197 HKSE:01244 HKSE:06622 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
09939:Hong Kong
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Website
https://www.kintor.com.cn
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.

Kintor Pharmaceutical Headlines